Selected article for: "SARS patient and symptom onset"
Author: Giamarellos-Bourboulis, Evangelos J.; Netea, Mihai G.; Rovina, Nikoletta; Akinosoglou, Karolina; Antoniadou, Anastasia; Antonakos, Nikolaos; Damoraki, Georgia; Gkavogianni, Theologia; Adami, Maria-Evangelia; Katsaounou, Paraskevi; Ntaganou, Maria; Kyriakopoulou, Magdalini; Dimopoulos, George; Koutsodimitropoulos, Ioannis; Velissaris, Dimitrios; Koufargyris, Panagiotis; Karageorgos, Athanassios; Katrini, Konstantina; Lekakis, Vasileios; Lupse, Mihaela; Kotsaki, Antigone; Renieris, George; Theodoulou, Danai; Panou, Vassiliki; Koukaki, Evangelia; Koulouris, Nikolaos; Gogos, Charalambos; Koutsoukou, Antonia
Title: Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
  • Cord-id: e9mepqvn
  • Document date: 2020_4_21
    • ID: e9mepqvn
    Snippet: Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by
    Document: Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.

    Search related documents:
    Co phrase search for related documents
    • absolute number and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • absolute number and lymphocyte blood count: 1
    • absolute number and lymphocyte count: 1, 2, 3
    • absolute number and lymphoid cell: 1
    • absolute patient lymphocyte count and acute respiratory syndrome: 1
    • absolute patient lymphocyte count and lymphocyte count: 1, 2
    • activation immune state and acute respiratory syndrome: 1, 2, 3
    • activation immune state and low expression: 1
    • acute chronic physiology health evaluation and admission value: 1, 2
    • acute chronic physiology health evaluation and lymphocyte blood count: 1, 2, 3
    • acute chronic physiology health evaluation and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute chronic physiology health evaluation apache and admission value: 1, 2
    • acute chronic physiology health evaluation apache and lymphocyte blood count: 1, 2
    • acute chronic physiology health evaluation apache and lymphocyte count: 1, 2, 3, 4, 5, 6, 7
    • acute immune dysregulation and low expression: 1
    • acute immune dysregulation and macrophage activation: 1
    • acute immune dysregulation and macrophage activation syndrome: 1
    • acute respiratory syndrome and admission value: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory syndrome and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45